MedTrace Logo

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

NCT06433609 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2026-07-14

No results posted yet for this study

Summary

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.

Conditions

Interventions

DRUG

SHR-A1811

Via intravenous infusion

DRUG

SHR-A1921

Via intravenous infusion

DRUG

Adebrelimab

Via intravenous infusion

DRUG

SHR-A2102

Via intravenous infusion

Sponsors & Collaborators

  • Beijing GoBroad Hospital

    lead OTHER

Principal Investigators

  • Wei Zhao · Beijing GoBroad Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2027-03-31
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06433609 on ClinicalTrials.gov